These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 9064971)

  • 1. [New aspects of ACE inhibitor treatment of heart failure].
    Dietz R; Osterziel KJ
    Z Kardiol; 1996; 85 Suppl 6():241-6. PubMed ID: 9064971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Rationale, characteristics and study design of PREAMI (Perindopril and Remodelling in the Elderly with Acute Myocardial Infraction)].
    Magrini G; Nicolosi GL; Chiariello M; Ferrari R; Remme P; Tavazzi L
    Ital Heart J; 2005 Nov; 6 Suppl 7():14S-23S. PubMed ID: 16485513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators.
    Cleland JG; Erhardt L; Murray G; Hall AS; Ball SG
    Eur Heart J; 1997 Jan; 18(1):41-51. PubMed ID: 9049514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapy of left ventricular dysfunction: implications of recent therapeutic trials and future directions for therapy.
    Pitt B
    Schweiz Med Wochenschr; 1993 Feb; 123(8):342-8. PubMed ID: 8095738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Vasodilator agents in chronic heart failure: which is the best option?].
    Corbalán R; Kunstmann S; Jalil J
    Rev Med Chil; 1993 Jan; 121(1):81-8. PubMed ID: 8235172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Significance of treatment of early forms and prevention of heart failure. Value of ACE inhibitors in therapy after myocardial infarct].
    Kleber FX; Baumann G
    Acta Med Austriaca; 1993; 20(4):95-9. PubMed ID: 8237284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Value of ACE inhibitors in heart failure (clinical aspects)].
    Riegger AJ
    Z Kardiol; 1992; 81 Suppl 4():93-6. PubMed ID: 1290309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Early therapeutic intervention in heart failure].
    Klein W; Dusleag J
    Acta Med Austriaca; 1992; 19(3):73-6. PubMed ID: 1414167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Indications for ACE inhibitors in the postinfarct period].
    Ertl G; Gaudron P; Neubauer S; Hu K; Zdrojewski T; Horn M; Kochsiek K
    Z Kardiol; 1994; 83 Suppl 4():65-74. PubMed ID: 7856283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of the renin-angiotensin system. Effect on mortality in patients with left ventricular systolic dysfunction.
    Pitt B
    Cardiol Clin; 1994 Feb; 12(1):101-14. PubMed ID: 8181019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Converting enzyme inhibitors and coronary failure].
    Castaigne A; Saal JP; Albo C; Verschuren P; Pham I
    Rev Prat; 1992 Dec; 42(20):2568-73. PubMed ID: 1299942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Current aspects of ACE inhibitor therapy from the cardiologic viewpoint].
    Klein W; Eber B; Gasser R; Stoschitzky K; Schumacher M; Fruhwald FM; Zweiker R
    Wien Med Wochenschr; 1996; 146(11):221-4. PubMed ID: 8928518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prevention with angiotensin-converting enzyme (ACE) inhibitors].
    Ertl G; Gaudron P; Neubauer S; Bauer B
    Z Kardiol; 1992; 81 Suppl 4():205-10. PubMed ID: 1290300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of ACE-inhibitors and beta-blockers on left ventricular remodeling in chronic heart failure.
    Khattar RS
    Minerva Cardioangiol; 2003 Apr; 51(2):143-54. PubMed ID: 12783070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Modern therapy of cardiac insufficiency].
    Stojsić D; Jelkić N
    Med Pregl; 1999; 52(3-5):113-24. PubMed ID: 10518395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The significance of converting enzyme inhibitor angiotensin I to angiotensin II in treatment of patients with coronary disease].
    Halawa B
    Pol Merkur Lekarski; 1998 Jan; 4(19):32-4. PubMed ID: 9553407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM; Sanoski CA; Spinler SA
    Pharmacotherapy; 2009 Jan; 29(1):31-48. PubMed ID: 19113795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
    Saha SA; Molnar J; Arora RR
    Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolving rationale for angiotensin-converting enzyme inhibition in chronic heart failure.
    Banerjee A; Talreja A; Sonnenblick EH; LeJemtel TH
    Mt Sinai J Med; 2003 Sep; 70(4):225-31. PubMed ID: 12968195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.